Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat ...

Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.

MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

We recently compiled a list of the Jim Cramer Recently Discussed These 17 Stocks And Chinese Hackers. In this article, we are ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Moderna's been anything but a high-flying growth stock in this investor's portfolio. So is it high time he gave up on this ...

Albert Bourla and other healthcare CEOs talked about the efficacy of vaccines and how public health could take a big turn for ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

CEO Stéphane Bancel emphasised saving cash as integral in the company’s bid to parlay Covid-19 profits into future profitability.